IHAM
CYTK icon

Integral Health Asset Management’s Cytokinetics CYTK Stock Holding History

Integral Health Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-100,000
Closed -$8.35M – 86
2023
Q4 		$8.35M Buy
+100,000
New +$3.62M 1.14% 39

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Integral Health Asset Management's CYTK Position: Q1 2026 in Review

Integral Health Asset Management increased its Cytokinetics (CYTK) stake by 14% in Q1 2026, buying an estimated $12.7M and bringing the position to 1,600,000 shares worth $105M. The position accounts for 5.04% of the portfolio, ranked #3.

Integral Health Asset Management first reported a position in CYTK in Q1 2020 and has held it in 25 quarters since. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Integral Health Asset Management held 1,600,000 shares of Cytokinetics worth $105M as of Q1 2026.
  • Integral Health Asset Management bought 200,000 Cytokinetics shares in Q1 2026, an estimated $12.7M.
  • Cytokinetics made up 5.04% of Integral Health Asset Management's portfolio in Q1 2026, its #3 holding.
  • Integral Health Asset Management first reported a position in Cytokinetics in Q1 2020 and has held it in 25 quarters since.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Integral Health Asset Management's 13F filing for Q1 2026, filed 15 May 2026.